Bcl-2 Receptor Expression in Patients With Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis Comparing Leiomyoma,Uterine Smooth Muscle Tumor of Uncertain Malignant Potential,and Leiomyosarcoma

Abstract

Objective: Bcl-2 protein is an apoptosis-inhibiting gene product that prevents the normal course of apoptotic cell death in a variety of cells. Additionally, bcl-2 can promote cell replication by reducing the requirement for growth factors. This protein seems, therefore, to play an important role in the growth of tumors. Our aim was to investigate the different expression of bcl-2 in uterine leiomyomas, smooth muscle tumors of uncertain malignant potential (STUMP), and leiomyosarcomas (LMS). Furthermore, the correlation between bcl-2 expression and various clinicopathologic parameters in leiomyosarcomas was assessed to evaluate its prognostic value.

Methods: This study included 26 cases of leiomyoma, 22 cases of STUMP, and 21 cases of LMS of the uterus, Bcl-2 expression was investigated by immunohistochemistry from paraffin-embedded tissue. The immunohistochemical findings were compared and correlated with different clinicopathologic paramters. Clinical information, including follow-up data, was obtained from the database of the Department of Gynecology and Obstetrics.

Results: Bcl-2 was present in 12 of 21 LMS, eight of 22 STUMP, and 20 of 25 leiomyomas. Significant differences regarding the frequency of bcl-2 expression and the staining intensity were observed between LMS and leiomyoma as well as between STUMP and leiomyoma (P < .05) but not between LMS and STUMP (P > .05). Regarding the outcome of uterine LMS, patients with bcl-2 positive tumors showed less vascular space involvement and longer overall survival (P < .05).

Conclusion: Bcl-2 was expressed more frequently and more strongly in leiomyomas compared with LMS and STUMP. Regarding the outcome of uterine LMS, patients with bcl-2-positive tumors showed less vascular space involvement and longer overall survival. The stronger bcl-2 expression in benign leiomyomas and the better clinical outcome of bcl-2-positive LMS indicate that this protein seems to act as a good prognostic factor. Further studies including larger numbers of patients are necessary to establish bcl-2 as a routine marker for improved prognosis in malignant uterine smooth muscle tumors.

Keywords

Uterine smooth muscle tumors bcl-2 expression clinicopathologic parameters

Get full access to this article

View all access options for this article.

References

1. Hockenberry DM . Bcl-2 in cancer, development and apoptosis. J Cell Sci 1994;18:51-55.

2. Reed JC . Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.

3. Reed JC , Talwar HS , Cuddy M , et al. Mitochondrial protein p26 bcl-2 reduces growth factor requirements of NIH3t3 fibroblast. Exp Cell Res 1991;195:277-283.

4. Nunez G , London L , Hockenberry D , et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoetic cell lines. J Immunol 1990;144:3602-3610.

5. Baretton GB , Diebold J , Christoforis G , et al. Apoptosis and immunhistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996;77:255-264.

6. Nakanishi H , Ohsawa M , Naka N , Uchida A , Ochi T , Aozaka K . Immunhistochemical detection of bcl-2 and p53 protein and apoptosis in soft tissue sarcoma: Their correlation with prognosis. Oncology 1997;54:238-244.

7. Nakopoulou L , Vourlakou C , Zervas A , Tzonou A , Gakipoulou H , Dimopoulos MA . The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29:146-154.

8. Zhai YL , Nikaido T , Toki T , Shiozwawa A , Orii A , Fujii S . Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 1999;80(10):1658-1664.

9. Mittal K , Demopoulos RI . MIB-1 (KI-67), p 53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Human Pathol 2001;32(9):984-987.

10.

10. Clement PB . The pathology of uterine smooth muscle tumors and mixed endometrial stromal smooth muscle tumors: A selective review with emphasis on recent advances. Int J Gynecol Pathol 2000;19:39-55.

11.

11. Zaloudek CJ , Hendrickson MR . Mesenchymal tumors of the uterus. In: Kurman RJ , ed. Blaustein's pathology of the female genital tract. New York: Spriger Verlag, 2002:561-615.

12.

12. Schwartz Z , Dgani R , Lancet M , Kessler I . Uterine sarcoma in Israel: A study of 104 cases. Gynecol Oncol 1985;20:354-363.

13.

13. Evans HL , Chawla SP , Simpson C , Finn KP . Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988;62:2239-2247.

14.

14. Nordal RR , Kristensen GB , Kaern J , Stenwig AE , Pettersen EO , Trope CG . The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1995;34:797-802.

15.

15. Vollenhoven BJ , Lawrence AS , Healy DL . Uterine fibroids: A clinical review. Br J Obstet Gynecol 1990;97:285-298.

16.

16. Matuso H , Maruo T , Samoto T . Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82:293-299.

17.

17. Khurana KK , Singh SB , Tatum AH , Schulz V , Badawy SZ . Maintenance of increased bcl-2 exprssion in uterine leiomyomas after GnRH agonist therapy. J. Reprod Med 1999;44(6):487-492.

18.

18. Bell SW , Kempson RL , Hendrickson MR . Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18(6):535-558.

19.

19. Kaplan EL , Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.

20.

20. Kahanpää KV , Wahlström T , Gröhn P , Heinonnen E , Nieminen U , Widholm O . Sarcomas of the uterus: A clinicopathologic study of 119 patients. Obstet Gynecol 1986;67:417-424.

21.

21. Salazar OM , Bonfiglio EA , Patten SF , et al. Uterine sarcomas Natural history, treatment and prognosis. Cancer 1978;42:1152-1160.

22.

22. Bazzocchi F , Brandi G , Pileri S , Mancuso A , Massaro A , Martinelli G . Clinical and pathologic prognostic features of leiomyosarcoma of the uterus. Tumori 1983;69:75-77.

23.

23. Pezzella F , Turley H , Kuzu I , et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.

24.

24. Silvestrini R , Veneroni S , Daidone MG , et al. The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.

25.

25. Fontanini G , Vignati S , Bigini D , et al. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell-lung cancer. Br J Cancer 1995;71:1003-1007.

26.

26. Brambilla E , Negoescu A , Gazzeri S , et al. Apoptosis-related factors p53, bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-1952.